← UroGen Pharma Ltd.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss) Attributable to Parent | ($1.9m) |
($20.0m)
-930.40%
|
($75.7m)
-278.28%
|
($105.1m)
-38.98%
|
($128.5m)
-22.20%
|
($110.8m)
+13.75%
|
($109.8m)
+0.94%
|
($102.2m)
+6.87%
|
($126.9m)
-24.09%
|
($153.5m)
-20.98%
|
— | |
| Net Income (Loss) Available to Common Stockholders, Basic | ($4.4m) |
($20.8m)
-372.44%
|
($75.7m)
-263.30%
|
($105.1m)
-38.98%
|
($128.5m)
-22.20%
|
— | — | — | — | — | — | |
| Depreciation, Depletion and Amortization | $213k | $207k | $400k | $300k | $400k | $831k | $924k | $802k | $329k | $307k | $2.6m | |
| Share-based Payment Arrangement, Noncash Expense | $2.0m | $6.3m | $30.6m | $30.0m | $28.0m | $23.1m | $10.6m | $9.3m | $13.1m | $12.0m | $16.1m | |
| Share-based Payment Arrangement, Expense | $2.0m | $6.3m | $30.6m | $30.0m | $28.0m | $23.1m | $10.6m | $9.3m | $13.1m | $12.0m | $16.1m | |
| Operating Lease, Impairment Loss | — | — | — | $0 | — | — | $0 | $0 | $0 | $0 | — | |
| Nonoperating Income (Expense) | — | — | — | — | — | — | $72k | $838k | ($229k) | ($670k) | — | |
| Other Nonoperating Income (Expense) | — | — | — | ($284k) | — | — | — | — | — | — | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | $83k | ($83k) | — | — | $7.0m | $4.7m | $987k | $2.7m | $4.9m | $12.8m | ($69.1m) | |
| Increase (Decrease) in Inventories | $105k | $211k | ($316k) | — | $2.0m | $2.9m | $362k | $1.3m | $3.6m | $7.2m | ($17.5m) | |
| Inventory Write-down | — | — | — | — | — | — | $870k | $0 | — | — | — | |
| Net Cash Provided by (Used in) Operating Activities | $4.2m |
($9.6m)
-328.48%
|
($37.3m)
-290.07%
|
($71.0m)
-90.22%
|
($105.9m)
-49.10%
|
($84.9m)
+19.83%
|
($87.6m)
-3.14%
|
($76.4m)
+12.77%
|
($96.8m)
-26.70%
|
($162.4m)
-67.87%
|
($158.9m)
+2.17%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $695k | $271k | $560k | $325k | $1.2m | $752k | $254k | $194k | $295k | $289k | ($218k) | |
| Cash, Cash Equivalents, and Short-term Investments | — | — | — | — | — | — | — | $141.5m | $241.7m | $120.5m | — | |
| Gain (Loss) on Sale of Investments | — | — | ($100k) | — | — | — | — | — | — | — | — | |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale | — | — | — | — | — | $54.3m | $64.3m | $49.1m | $107.7m | $139.2m | — | |
| Unrealized Gain (Loss) on Investments | — | $0 | $100k | — | — | — | — | — | — | — | — | |
| Net Cash Provided by (Used in) Investing Activities | ($793k) | ($36.4m) | $35.3m | ($145.6m) | $93.2m | $4.1m | $1.1m | ($953k) | ($20.6m) | $61.6m | $40.1m | |
| Cash flows from financing activities: | ||||||||||||
| Proceeds from Issuance of Long-term Debt | — | — | — | — | — | — | $95.8m | $0 | $24.5m | $0 | $65.3m | |
| Proceeds from Issuance of Common Stock | — | $60.8m | $64.2m | $161.7m | $15.9m | $0 | — | $67.4m | $151.2m | $39.8m | $39.8m | |
| Net Cash Provided by (Used in) Financing Activities | ($9k) |
$61.6m
+684377.78%
|
$66.4m
+7.85%
|
$165.2m
+148.79%
|
$16.5m
-90.00%
|
$72.3m
+337.58%
|
$97.1m
+34.31%
|
$116.9m
+20.38%
|
$194.6m
+66.44%
|
$39.9m
-79.49%
|
$105.3m
+163.77%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $3.4m | $15.6m | $64.4m | ($51.4m) | $3.9m | ($8.5m) | $10.6m | $39.6m | $77.2m | ($61.0m) | $80.5m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | — | $404k | $2.4m | $3.7m | $740k | $61k | $1.5m | $873k | $321k | $2.0m | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, Net | — | — | — | — | — | — | — | — | — | $3.0m | — | |
| Additional Financial Items | ||||||||||||
| Foreign Currency Transaction Gain (Loss), before Tax | — | $3k | — | — | — | — | — | — | — | — | — | |
| General and Administrative Expense | $6.4m | $8.8m | $39.6m | $60.2m | — | — | — | — | — | — | — | |
| Income Tax Expense (Benefit) | — | $19k | $125k | — | $3.4m | $1.4m | $1.8m | $3.9m | $2.8m | $78k | — | |
| Investment Income, Interest | — | — | — | — | $2.0m | $365k | $938k | $2.6m | $8.9m | $6.0m | — | |
| Operating Expenses | — | — | $76.5m | $109.5m | — | — | — | — | — | — | — | |
| Operating Lease, Expense | — | — | — | $1.2m | — | — | — | — | — | — | — | |
| Payments of Financing Costs | — | $42k | $215k | — | — | — | — | — | — | — | — |